drugset
drugset / Trial / NCT01159067

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

NCT01159067 ↗

Phase 2 Terminated 1 enrolled City of Hope Medical Center
NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload. PURPOSE: This pilot clinical trial studies safety and tolerability of deferasirox in hematopoietic stem cell transplant recipients who have iron overload. Effect of low dose deferasirox on labile plasma iron is also examined.

Timeline

Start
2010-07
Primary completion
2011-08-09
Completion
2011-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown 10 mg/kg Oral

Indications

Burkitt lymphoma Hodgkins lymphoma MALT lymphoma acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(15;17)(q24;q21) acute myeloid leukemia, t(16;16)(p13.1;q22) atypical chronic myeloid leukemia, BCR-ABL1 negative blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic eosinophilic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma chronic myelomonocytic leukemia chronic neutrophilic leukemia diffuse large B-cell lymphoma disorder of iron metabolism and transport female breast carcinoma gestational trophoblastic neoplasm hairy cell leukemia large-cell immunoblastic lymphoma leukemia, myeloid, accelerated-phase malignant testicular germ cell tumor mantle cell lymphoma mycosis fungoides and variants myelodysplastic syndrome myeloproliferative neoplasm, unclassifiable neuroblastoma nodal marginal zone B-cell lymphoma ovarian carcinoma ovarian germ cell tumor plasma cell myeloma primary myelofibrosis splenic marginal zone lymphoma